drugset / Trial / NCT00144131

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

NCT00144131

Phase 2 Completed 750 enrolled Amgen
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will compare the efficacy (non-inferiority) of darbepoetin alfa (Aranesp®) extended dose schedule administration (EDS) versus darbepoetin alfa administered once per week (QW) in the treatment of anemia in subjects with non-myeloid malignancies receiving multi-cycle chemotherapy.

Timeline

Start
2005-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 150 ug
Subject Darbepoetin alfa Protein / enzyme biologic 300 ug
Subject Darbepoetin alfa Protein / enzyme biologic 500 ug

Indications